1 min read
SELLAS Life Sciences Group Begins $150 Million Stock Offering
The company plans to grant underwriters a 30-day option to buy additional shares.

SELLAS Life Sciences Group, Inc. (SLS) began an underwritten $150 million public offering of common stock Tuesday, Nov. 17, and plans to grant underwriters a 30-day option to purchase additional shares.
The offering follows positive results from REGAL, the company’s Phase 3 trial involving patients with acute myeloid leukemia. SLS shares rose more than 281% after the trial results. The trial showed a statistically significant improvement in overall survival.